logo
Plus   Neg
Share
Email

FDA Advisory Committee To Review Orexigen's Obesity Drug Contrave - Quick Facts

Orexigen Therapeutics Inc. (OREX) said that the FDA advisory committee will review the company's new drug application for Contrave for the treatment of obesity on December 7, 2010.

The FDA has already set January 31, 2011 as the Prescription Drug User Fee Act action date for Contrave.

Contrave is an investigational combination therapy believed to address both physiological and behavioral drivers of obesity.

In clinical trials, Contrave was shown to help obese patients initiate and sustain significant weight loss, improve important markers of cardiometabolic risk and increase ability to control eating.

For comments and feedback contact: editorial@rttnews.com

Follow RTT